Table of Content

Executive Summary

1 Product Definition and Market Scope
1.1 Inclusion and Exclusion
1.2 Scope of Work
1.3 Key Questions Answered in the Report

2 Research Methodology
2.1 Primary Data Sources
2.2 Secondary Data Sources
2.3 Market Estimation Model
2.4 Criteria for Company Profiling

3 Market Overview
3.1 Clinical Importance of Regenerative Medicine
3.2 Market Footprint
3.3 Impact of COVID-19

4 Market Dynamics
4.1 Impact Analysis
4.2 Market Drivers
4.2.1 Increasing Consolidation in the Regenerative Medicines Market
4.2.2 Rising Number of Clinical Trials
4.2.3 Favorable Regulatory Environment
4.2.4 Rising Awareness for Stem Cell Therapeutics
4.3 Market Restraints
4.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy
4.3.2 Exorbitant Cost of Next-Generation Therapies
4.4 Opportunities
4.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies
4.4.2 Multiple Investments in Expansion of cGMP Units
4.4.3 Innovations in Regenerative Medicine

5 Industry Insights
5.1 Overview
5.2 Legal and Regulatory Framework in the U.S.
5.2.1 Cell and Gene Therapy
5.2.1.1 Cell and Gene Therapy Manufacturing QC
5.2.1.1.1 Product Testing
5.2.1.1.1.1 Microbial Testing
5.2.1.1.1.2 Identity
5.2.1.1.1.3 Purity
5.2.1.1.1.4 Potency
5.2.1.1.1.5 Viability
5.2.1.1.1.6 Cell Number/Dose
5.2.2 Stem Cell Therapy
5.2.3 Tissue-Engineered Products
5.3 Legal and Regulatory Framework in Europe
5.4 Legal and Regulatory Framework in Asia-Pacific
5.4.1 China
5.4.2 Japan

6 Global Regenerative Medicines Market: Competitive Insights
6.1 Overview
6.2 Synergistic Activities
6.3 Product Approval
6.4 Mergers and Acquisitions
6.5 Business Expansion and Funding
6.6 Product Launches and Upgradations
6.7 Market Share Analysis, 2019-2020
6.7.1 Market Share Analysis for Global Regenerative Medicines Market (Tissue Engineering), 2019-2020
6.7.2 Market Share Analysis for Global Regenerative Medicines Market (Cell and Gene Therapy), 2019-2020
6.7.3 Market Share Analysis for Global Regenerative Medicines Market (Stem Cell Therapy), 2019-2020
6.8 Growth Share Analysis
6.8.1 Growth Share Analysis (by Company)
6.8.2 Growth Share Analysis (by Product)
6.8.3 Growth Share Analysis (by Application)

7 Global Regenerative Medicines Market (by Product Type), $Million, 2019-2030
7.1 Overview
7.2 Tissue Engineering
7.2.1 Allogeneic Tissue
7.2.2 Autologous Tissue
7.2.3 Xenogeneic Tissue
7.2.4 Synthetic Tissue
7.2.5 Other Tissues
7.3 Stem Cells
7.3.1 Stem Cell Services
7.3.2 Stem Cell Therapy
7.4 Cell and Gene Therapy
7.4.1 Cell Therapy
7.4.1.1 Cell Therapy (by Type)
7.4.2 Gene Therapy

8 Global Regenerative Medicines Market (by Application), $Million, 2019-2030
8.1 Overview
8.2 Orthopedic and Musculoskeletal
8.3 Oncology
8.4 Wound Care
8.5 Cardiology
8.6 Immunology
8.7 Dermatology
8.8 Other Applications

9 Global Regenerative Medicines Market (by Region), $Million, 2019-2030
9.1 Overview
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 Italy
9.3.4 U.K.
9.3.5 Spain
9.3.6 Russia
9.3.7 Netherlands
9.3.8 Rest-of-Europe
9.4 Asia-Pacific
9.4.1 China
9.4.2 Japan
9.4.3 South Korea
9.4.4 Australia
9.4.5 India
9.4.6 Singapore
9.4.7 Rest-of-Asia-Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest-of-Latin America
9.6 Rest-of-the-World (RoW)

10 Company Profiles
10.1 Overview
10.2 AbbVie, Inc.
10.2.1 Company Overview
10.2.2 Role of AbbVie, Inc. in Global Regenerative Medicines Market
10.2.3 Financials
10.2.4 Key Insights About Financial Health of the Company
10.2.5 SWOT Analysis
10.3 Baxter International Inc.
10.3.1 Company Overview
10.3.2 Role of Baxter International Inc. in Global Regenerative Medicines Market
10.3.3 Financials
10.3.4 Key Insights About Financial Health of the Company
10.3.5 SWOT Analysis
10.4 Becton, Dickinson and Company
10.4.1 Company Overview
10.4.2 Role of Becton, Dickinson and Company in the Global Regenerative Medicines Market
10.4.3 Financials
10.4.4 Key Insights About Financial Health of the Company
10.4.5 SWOT Analysis
10.5 Dendreon Pharmaceuticals LLC.
10.5.1 Company Overview
10.5.2 Role of Dendreon Pharmaceuticals LLC. in the Global Regenerative Medicines Market
10.5.3 SWOT Analysis
10.6 F. Hoffmann-La Roche Ltd
10.6.1 Company Overview
10.6.2 Role of F. Hoffmann-La Roche Ltd. in the Global Regenerative Medicines Market
10.6.3 Financials
10.6.4 Key Insights About Financial Health of the Company
10.6.5 SWOT Analysis
10.7 FUJIFILM Holdings Corporation
10.7.1 Company Overview
10.7.2 Role of FUJIFILM Holdings Corporation in the Global Regenerative Medicines Market
10.7.3 Financials
10.7.4 Key Insights About Financial Health of the Company
10.7.5 SWOT Analysis
10.8 Gilead Sciences, Inc.
10.8.1 Company Overview
10.8.2 Role of Gilead Sciences, Inc. in the Global Regenerative Medicines Market
10.8.3 Financials
10.8.4 Key Insights About Financial Health of the Company
10.8.5 SWOT Analysis
10.9 Integra LifeSciences Holdings Corporation
10.9.1 Company Overview
10.9.2 Role of Integra LifeSciences Holdings Corporation in Global Regenerative Medicines Market
10.9.3 Financials
10.9.4 Key Insights About Financial Health of the Company
10.9.5 SWOT Analysis
10.1 Johnson & Johnson
10.10.1 Company Overview
10.10.2 Role of Johnson & Johnson in the Global Regenerative Medicines Market
10.10.3 Financials
10.10.4 Key Insights About Financial Health of the Company
10.10.5 SWOT Analysis
10.11 Medtronic plc
10.11.1 Company Overview
10.11.2 Role of Medtronic plc in the Global Regenerative Medicines Market
10.11.3 Financials
10.11.4 Key Insights About Financial Health of the Company
10.11.5 SWOT Analysis
10.12 Mesoblast Ltd
10.12.1 Company Overview
10.12.2 Role of Mesoblast Ltd in the Global Regenerative Medicines Market
10.12.3 Financials
10.12.4 Key Insights About Financial Health of the Company
10.12.5 SWOT Analysis
10.13 Novartis International AG
10.13.1 Company Overview
10.13.2 Role of Novartis International AG in the Global Regenerative Medicines Market
10.13.3 Financials
10.13.4 Key Insights About Financial Health of the Company
10.13.5 SWOT Analysis
10.14 NuVasive, Inc.
10.14.1 Company Overview
10.14.2 Role of NuVasive, Inc. in the Global Regenerative Medicines Market
10.14.3 Financials
10.14.4 Key Insights About Financial Health of the Company
10.14.5 SWOT Analysis
10.15 Organogenesis Holdings Inc.
10.15.1 Company Overview
10.15.2 Role of Organogenesis Holdings, Inc. in the Global Regenerative Medicines Market
10.15.3 Financials
10.15.4 Key Insights About the Financial Health of the Company
10.15.5 SWOT Analysis
10.16 Smith & Nephew plc
10.16.1 Company Overview
10.16.2 Role of Smith & Nephew plc in the Global Regenerative Medicines Market
10.16.3 Financials
10.16.4 Key Insights About Financial Health of the Company
10.16.5 SWOT Analysis
10.17 Stryker Corporation
10.17.1 Company Overview
10.17.2 Role of Stryker Corporation in the Global Regenerative Medicines Market
10.17.3 Financials
10.17.4 Key Insights About Financial Health of the Company
10.17.5 SWOT Analysis
10.18 Vericel Corporation
10.18.1 Company Overview
10.18.2 Role of Vericel Corporation in the Global Regenerative Medicines Market
10.18.3 Financials
10.18.4 Key Insights About Financial Health of the Company
10.18.5 SWOT Analysis
10.19 Zimmer Biomet Holdings, Inc.
10.19.1 Company Overview
10.19.2 Role of Zimmer Biomet Holdings, Inc. in the Global Regenerative Medicines Market
10.19.3 Financials
10.19.4 Key Insights About Financial Health of the Company
10.19.5 SWOT Analysis
 



List of Tables


Table 3.1: Key Products of Cell and Gene Therapy Market
Table 4.1: Impact Analysis
Table 4.2: Key Cell and Gene Therapies with FDA Expedited Review
Table 4.3: Range of Cost for Regenerative Therapies
Table 7.1: List of Key Products
Table 7.2: List of Key Products
Table 7.3: List of Key Products
Table 7.4: List of Key Products
Table 7.5: List of Key Products
Table 7.6: List of Key Services
Table 7.7: List of Key Products
Table 7.8: List of Key Products
Table 7.9: List of Key Products
List of Figures
Figure 1: Global Clinical Landscape for Regenerative Medicine, 2019
Figure 2: Impact Analysis on the Global Regenerative Medicines Market
Figure 3: Global Regenerative Medicines Market (by Product), $Million, 2019 and 2030
Figure 4: Global Regenerative Medicines Market (by Application), $Million, 2019 and 2030
Figure 5: Global Regenerative Medicines Market (by Region), Market Snapshot
Figure 6: Global Regenerative Medicines Market (by Companies Profiled), Market Snapshot
Figure 1.1: Global Regenerative Medicines Market Segmentation
Primary Research Methodology
Figure 2.1: Bottom-Up Approach (Segment-Wise Analysis)
Figure 2.2: Top-Down Approach (Segment-Wise Analysis)
Figure 3.1: Global Regenerative Medicines Market, $Million, 2019-2030
Figure 3.2: Impact of COVID-19 on Global Regenerative Medicines Market
Figure 4.1: Number of Clinical Trials for ATMP (by Phase), 2019
Figure 6.1: Share of Key Developments and Strategies, January 2017-February 2021
Figure 6.2: Share of Synergistic Activities, January 2017-February 2021
Figure 6.3: Share of Product Approvals (by Company), January 2017-February 2020
Figure 6.4: Share of Mergers and Acquisitions (by Company), January 2017-February 2021
Figure 6.4: Business Expansion Activities Share, January 2011-February 2021
Figure 6.5: Share of Product Launches and Upgradations, January 2017-February 2021
Figure 6.6: Market Share Analysis for Global Regenerative Medicines Market (Tissue Engineering), 2019 and 2020
Figure 6.7: Market Share Analysis for Global Regenerative Medicines Market (Cell and Gene Therapy), 2019 and 2020
Figure 6.8: Market Share Analysis for Global Regenerative Medicines Market (Stem Cell Therapy), 2019 and 2020
Figure 6.9: Growth Share Analysis for Global Regenerative Medicines Market (by Company), 2020
Figure 6.10: Growth Share Analysis for Global Regenerative Medicines Market (by Product), 2020-2030
Figure 6.11: Growth Share Analysis for Global Regenerative Medicines Market (by Application), 2020-2030
Figure 7.1: Global Regenerative Medicines Market (by Product Type), $Million, 2019 and 2030
Figure 7.2: Global Regenerative Medicines Market (by Tissue Engineering), $Million, 2019-2030
Figure 7.3: Global Regenerative Medicines Market (Allogeneic Tissue), $Million, 2019-2030
Figure 7.4: Global Regenerative Medicines Market (Autologous Tissue), $Million, 2019-2030
Figure 7.5: Global Regenerative Medicines Market (Xenogeneic Tissue), $Million, 2019-2030
Figure 7.6: Global Regenerative Medicines Market (Synthetic Tissue), $Million, 2019-2030
Figure 7.7: Global Regenerative Medicines Market (Other Tissues), $Million, 2019-2030
Figure 7.8: Global Regenerative Medicines Market (by Stem Cells), $Million, 2019-2030
Figure 7.9: Global Regenerative Medicines Market (Stem Cell Services), $Million, 2019-2030
Figure 7.10: Global Regenerative Medicines Market (Stem Cell Therapy), $Million, 2019-2030
Figure 7.11: Global Regenerative Medicines Market (by Cell and Gene Therapy), $Million, 2019-2030
Figure 7.12: Global Regenerative Medicines Market (by Cell Therapy), $Million, 2019-2030
Figure 7.13: Global Regenerative Medicines Market (by Cell Therapy Type), $Million, 2019 and 2030
Figure 7.14: Global Regenerative Medicines Market (Gene Therapy), $Million, 2019-2030
Figure 8.1: Global Regenerative Medicines Market (by Application), $Million, 2019 and 2030
Figure 8.2: Global Regenerative Medicines Market (Orthopedic and Musculoskeletal), $Million, 2019-2030
Figure 8.3: Global Regenerative Medicines Market (Oncology), $Million, 2019-2030
Figure 8.4: Global Regenerative Medicines Market (Wound Care), $Million, 2019-2030
Figure 8.5: Global Regenerative Medicines Market (Cardiology), $Million, 2019-2030
Figure 8.6: Global Regenerative Medicines Market (Immunology), $Million, 2019-2030
Figure 8.7: Global Regenerative Medicines Market (Dermatology), $Million, 2019-2030
Figure 8.8: Global Regenerative Medicines Market (Other Applications), $Million, 2019-2030
Figure 9.1: Global Regenerative Medicines Market (by Region), Market Snapshot
Figure 9.2: North America: Market Dynamics
Figure 9.3: North America Regenerative Medicines Market, $Million, 2019-2030
Figure 9.4: North America Regenerative Medicines Market (by Country), $Million, 2019 Vs. 2030
Figure 9.5: U.S. Regenerative Medicines Market, $Million, 2019-2030
Figure 9.6: U.S. Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.7: Canada Regenerative Medicines Market, $Million, 2019-2030
Figure 9.8: Canada Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.9: Europe: Market Dynamics
Figure 9.10: Europe Regenerative Medicines Market, $Million, 2019-2030
Figure 9.11: Europe Regenerative Medicines Market (by Country), $Million, 2019 Vs. 2030
Figure 9.12: Germany Regenerative Medicines Market, $Million, 2019-2030
Figure 9.13: Germany Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.14: France Regenerative Medicines Market, $Million, 2019-2030
Figure 9.15: France Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.16: Italy Regenerative Medicines Market, $Million, 2019-2030
Figure 9.17: Italy Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.18: U.K. Regenerative Medicines Market, $Million, 2019-2030
Figure 9.19: U.K. Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.20: Spain Regenerative Medicines Market, $Million, 2019-2030
Figure 9.21: Spain Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.22: Russia Regenerative Medicines Market, $Million, 2019-2030
Figure 9.23: Russia Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.24: Netherlands Regenerative Medicines Market, $Million, 2019-2030
Figure 9.25: Netherlands Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.26: Rest-of-Europe Regenerative Medicines Market, $Million, 2019-2030
Figure 9.27: Rest-of-Europe Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.28: Asia-Pacific: Market Dynamics
Figure 9.29: Asia-Pacific Regenerative Medicines Market, $Million, 2019-2030
Figure 9.30: Asia-Pacific Regenerative Medicines Market (by Country), $Million, 2019 Vs. 2030
Figure 9.31: China Regenerative Medicines Market, $Million, 2019-2030
Figure 9.32: China Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.33: Japan Regenerative Medicines Market, $Million, 2019-2030
Figure 9.34: Japan Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.35: South Korea Regenerative Medicines Market, $Million, 2019-2030
Figure 9.36: South Korea Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.37: Australia Regenerative Medicines Market, $Million, 2019-2030
Figure 9.38: Australia Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.39: India Regenerative Medicines Market, $Million, 2019-2030
Figure 9.40: India Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.41: Singapore Regenerative Medicines Market, $Million, 2019-2030
Figure 9.42: Singapore Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.43: Rest-of-Asia-Pacific Regenerative Medicines Market, $Million, 2019-2030
Figure 9.44: Rest-of-Asia-Pacific Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.45: Latin America: Market Dynamics
Figure 9.46: Latin America Regenerative Medicines Market, $Million, 2019-2030
Figure 9.47: Latin America Regenerative Medicines Market (by Country), $Million, 2019 Vs. 2030
Figure 9.48: Brazil Regenerative Medicines Market, $Million, 2019-2030
Figure 9.49: Brazil Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.50: Mexico Regenerative Medicines Market, $Million, 2019-2030
Figure 9.51: Mexico Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.52: Rest-of-Latin America Regenerative Medicines Market, $Million, 2019-2030
Figure 9.53: Rest-of-Latin America Regenerative Medicines Market (by Product), $Million, 2019-2030
Figure 9.54: Rest-of-the-World Regenerative Medicines Market, $Million, 2019-2030
Figure 10.1: Total Number of Companies Profiled
Figure 10.2: AbbVie, Inc.: Overall Product Portfolio
Figure 10.3: AbbVie, Inc.: Overall Financials, 2018-2020
Figure 10.4: AbbVie, Inc.: Revenue (by Segment), 2018-2020
Figure 10.5: AbbVie, Inc.: Revenue (by Region), 2018-2020
Figure 10.6: AbbVie, Inc.: R&D Expenditure, 2018-2020
Figure 10.7: AbbVie, Inc.: SWOT Analysis
Figure 10.8: Baxter International Inc.: Overall Product Portfolio
Figure 10.9: Baxter International Inc.: Overall Financials, 2018-2020
Figure 10.10: Baxter International Inc.: Revenue (by Segment), 2018-2020
Figure 10.11: Baxter International Inc.: Revenue (by Region), 2018-2020
Figure 10.12: Baxter International Inc.: R&D Expenditure, 2018-2020
Figure 10.13: bioM?rieux SA: SWOT Analysis
Figure 10.14: Becton, Dickinson and Company: Overall Service Portfolio
Figure 10.15: Becton, Dickinson and Company.: Overall Financials, 2018-2020
Figure 10.16: Becton, Dickinson and Company: Revenue (by Segment), 2018-2020
Figure 10.17: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
Figure 10.18: Becton, Dickinson and Company: R&D Expenditure, 2018-2020
Figure 10.19: Becton, Dickinson and Company: SWOT Analysis
Figure 10.20: Dendreon Pharmaceuticals LLC.: Product Portfolio
Figure 10.21: Dendreon Pharmaceuticals LLC.: SWOT Analysis
Figure 10.22: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
Figure 10.23: F. Hoffmann-La Roche Ltd.: Pipeline Portfolio
Figure 10.24: F. Hoffmann-La Roche Ltd.: Overall Financials, 2018-2020
Figure 10.25: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), 2018-2020
Figure 10.26: F. Hoffmann-La Roche Ltd.: Revenue (by Region), 2018-2020
Figure 10.27: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020
Figure 10.28: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 10.29: FUJIFILM Holdings Corporation: Overall Product Portfolio
Figure 10.30: FUJIFILM Holdings Corporation: Overall Financials, 2017-2019
Figure 10.31: FUJIFILM Holdings Corporation: Revenue (by Segment), 2017-2019
Figure 10.32: FUJIFILM Holdings Corporation: Revenue (by Region), 2017-2019
Figure 10.33: FUJIFILM Holdings Corporation: R&D Expenditure, 2017-2019
Figure 10.34: FUJIFILM Holdings Corporation: SWOT Analysis
Figure 10.35: Gilead Sciences, Inc.: Product Portfolio
Figure 10.36: Gilead Sciences, Inc.: Pipeline Product Portfolio
Figure 10.37: Gilead Sciences, Inc.: Overall Financials, 2018-2020
Figure 10.38: Gilead Sciences, Inc.: Revenue (by Segment), 2018-2020
Figure 10.39: Gilead Sciences, Inc.: Revenue (by Region), 2018-2020
Figure 10.40: Gilead Sciences, Inc.: R&D Expenditure, 2018-2020
Figure 10.41: Gilead Sciences, Inc.: SWOT Analysis
Figure 10.42: Integra LifeSciences Holdings Corporation: Overall Product Portfolio
Figure 10.43: Integra LifeSciences Holdings Corporation: Overall Financials, 2018-2020
Figure 10.44: Integra LifeSciences Holdings Corporation: Revenue (by Segment), 2018-2020
Figure 10.45: Integra LifeSciences Holdings Corporation: Revenue (by Region), 2018-2020
Figure 10.46: Integra LifeSciences Holdings Corporation: R&D Expenditure, 2018-2020
Figure 10.47: Integra LifeSciences Holdings Corporation: SWOT Analysis
Figure 10.48: Johnson & Johnson: Product Portfolio
Figure 10.49: Johnson & Johnson: Overall Financials, 2018-2020
Figure 10.50: Johnson & Johnson: Revenue (by Segment), 2018-2020
Figure 10.51: Johnson & Johnson: Revenue (by Region), 2018-2020
Figure 10.52: Johnson & Johnson: R&D Expenditure, 2018-2020
Figure 10.53: Johnson & Johnson: SWOT Analysis
Figure 10.54: Medtronic plc: Product Portfolio
Figure 10.55: Medtronic plc: Overall Financials, 2018-2020
Figure 10.56: Medtronic plc: Revenue (by Segment), 2018-2020
Figure 10.57: Medtronic plc: Revenue (by Restorative Therapies Group), 2018-2020
Figure 10.58: Medtronic plc: Revenue (by Region), 2018-2020
Figure 10.59: Medtronic plc: R&D Expenditure, 2018-2020
Figure 10.60: Medtronic plc: SWOT Analysis
Figure 10.61: Mesoblast Ltd.: Product Portfolio
Figure 10.62: Mesoblast Ltd.: Product Portfolio
Figure 10.62: Mesoblast Ltd: Overall Financials, 2018-2020
Figure 10.63: Mesoblast Ltd: Revenue (by Segment), 2018-2020
Figure 10.64: Mesoblast Ltd: R&D Expenditure, 2018-2020
Figure 10.65: Mesoblast Ltd: SWOT Analysis
Figure 10.66: Novartis International AG: Product Portfolio
Figure 10.67: Novartis International AG: Pipeline Product Portfolio
Figure 10.68: Novartis International AG.: Overall Financials, 2018-2020
Figure 10.69: Novartis International AG: Revenue (by Segment), 2018-2020
Figure 10.70: Novartis International AG: Revenue (by Region), 2018-2020
Figure 10.71: Novartis International AG: R&D Expenditure, 2018-2020
Figure 10.72: Novartis International AG: SWOT Analysis
Figure 10.73: NuVasive, Inc.: Product Portfolio
Figure 10.74: NuVasive, Inc.: Overall Financials, 2018-2020
Figure 10.75: NuVasive, Inc.: Revenue (by Segment), 2018-2020
Figure 10.76: NuVasive, Inc.: Revenue (by Region), 2018-2020
Figure 10.77: NuVasive, Inc.: R&D Expenditure, 2018-2020
Figure 10.78: NuVasive, Inc.: SWOT Analysis
Figure 10.79: Organogenesis Holdings Inc.: Product Portfolio
Figure 10.80: Organogenesis Holdings Inc.: Overall Financials, 2017-2019
Figure 10.81: Organogenesis Holdings Inc.: Revenue (by Segment), 2017-2019
Figure 10.82: Organogenesis Holdings Inc.: R&D Expenditure, 2017-2019
Figure 10.83: Organogenesis Holdings Inc.: SWOT Analysis
Figure 10.84: Smith & Nephew plc: Product Portfolio
Figure 10.85: Smith & Nephew plc: Overall Financials, 2018-2020
Figure 10.86: Smith & Nephew plc: Revenue (by Segment), 2018-2020
Figure 10.87: Smith & Nephew plc: Revenue (by Region), 2018-2020
Figure 10.88: Smith & Nephew plc: R&D Expenditure, 2018-2020
Figure 10.89: Smith & Nephew plc: SWOT Analysis
Figure 10.90: Stryker Corporation: Product Portfolio
Figure 10.91: Stryker Corporation: Overall Financials, 2018-2020
Figure 10.92: Stryker Corporation: Revenue (by Segment), 2018-2020
Figure 10.93: Stryker Corporation: Revenue (by Region), 2018-2020
Figure 10.94: Stryker Corporation: R&D Expenditure, 2018-2020
Figure 10.95: Stryker Corporation: SWOT Analysis
Figure 10.96: Vericel Corporation: Product Portfolio
Figure 10.97: Vericel Corporation: Overall Financials, 2018-2020
Figure 10.98: Vericel Corporation: Revenue (by Segment), 2018-2020
Figure 10.99: Vericel Corporation: R&D Expenditure, 2018-2020
Figure 10.100: Vericel Corporation: SWOT Analysis
Figure 10.101: Zimmer Biomet Holdings, Inc.: Product Portfolio
Figure 10.102: Zimmer Biomet Holdings, Inc.: Overall Financials, 2018-2020
Figure 10.103: Zimmer Biomet Holdings, Inc.: Revenue (by Segment), 2018-2020
Figure 10.104: Zimmer Biomet Holdings, Inc.: Revenue (by Region), 2018-2020
Figure 10.105: Zimmer Biomet Holdings, Inc.: R&D Expenditure, 2018-2020
Figure 10.106: Zimmer Biomet Holdings, Inc.: SWOT Analysis